,22 To overcome these challenges, researchers are exploring strategies such as combining ACT with ICIs or enhancing the persistence of infused cells with cytokines like interleukin-2 (IL-2).23, 24, 25 OVs represent an innovative class of therapies that selectively infect and destroy tumor cells while sparing healthy tissues.26 This evidence concerns the gene IL2 and neoplasm.